EXTON, Penn., Jan. 11, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that the new ViroPharma corporate website is now online. The new website, available at www.viropharma.com, was designed and developed to provide relevant information about the company, its product candidates in the clinical pipeline, and its marketed product, Vancocin(r) Pulvules(r).
The new website will provide patients, healthcare providers, and the investment community with new features and information, including:
-- Detailed investor-specific pages, including an expanded
corporate governance section, stock analysis tools,
searchable SEC filings, and an ownership summary page;
-- Therapeutic focus sections, designed to provide an overview
of the areas of corporate clinical and commercial focus;
-- Clinical pipeline pages with information on the status of
product candidates in development;
-- Additional information regarding ViroPharma's marketed
product, Vancocin Pulvules.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(r) Pulvules(r), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_PI.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at www.viropharma.com.